JP2017532037A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017532037A5 JP2017532037A5 JP2017518907A JP2017518907A JP2017532037A5 JP 2017532037 A5 JP2017532037 A5 JP 2017532037A5 JP 2017518907 A JP2017518907 A JP 2017518907A JP 2017518907 A JP2017518907 A JP 2017518907A JP 2017532037 A5 JP2017532037 A5 JP 2017532037A5
- Authority
- JP
- Japan
- Prior art keywords
- fragment
- seq
- antibody
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims description 104
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 41
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 31
- 210000004027 cell Anatomy 0.000 claims description 14
- 235000001014 amino acid Nutrition 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 108091033319 polynucleotide Proteins 0.000 claims description 10
- 102000040430 polynucleotide Human genes 0.000 claims description 10
- 239000002157 polynucleotide Substances 0.000 claims description 10
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 9
- 150000001413 amino acids Chemical class 0.000 claims description 9
- 102000050320 human TNFRSF4 Human genes 0.000 claims description 9
- 239000000427 antigen Substances 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 230000004614 tumor growth Effects 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 6
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 3
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 16
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 16
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 241000282560 Macaca mulatta Species 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- 108090000174 Interleukin-10 Proteins 0.000 description 4
- 108090000176 Interleukin-13 Proteins 0.000 description 4
- 108010002616 Interleukin-5 Proteins 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 3
- 241000282567 Macaca fascicularis Species 0.000 description 3
- 101100005714 Macaca fascicularis CD4 gene Proteins 0.000 description 3
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 3
- 230000009696 proliferative response Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 101100153537 Mus musculus Tnfrsf4 gene Proteins 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462062431P | 2014-10-10 | 2014-10-10 | |
| US62/062,431 | 2014-10-10 | ||
| PCT/US2015/054490 WO2016057667A1 (en) | 2014-10-10 | 2015-10-07 | Humanized anti-ox40 antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020187650A Division JP2021036887A (ja) | 2014-10-10 | 2020-11-11 | ヒト化抗ｏｘ４０抗体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017532037A JP2017532037A (ja) | 2017-11-02 |
| JP2017532037A5 true JP2017532037A5 (Direct) | 2018-11-15 |
| JP6794348B2 JP6794348B2 (ja) | 2020-12-09 |
Family
ID=55130798
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017518907A Active JP6794348B2 (ja) | 2014-10-10 | 2015-10-07 | ヒト化抗ｏｘ４０抗体及びその使用 |
| JP2020187650A Withdrawn JP2021036887A (ja) | 2014-10-10 | 2020-11-11 | ヒト化抗ｏｘ４０抗体及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020187650A Withdrawn JP2021036887A (ja) | 2014-10-10 | 2020-11-11 | ヒト化抗ｏｘ４０抗体及びその使用 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US9738723B2 (Direct) |
| EP (1) | EP3204422B1 (Direct) |
| JP (2) | JP6794348B2 (Direct) |
| KR (1) | KR20170064550A (Direct) |
| CN (1) | CN107074953A (Direct) |
| AR (1) | AR102239A1 (Direct) |
| AU (1) | AU2015328090A1 (Direct) |
| BR (1) | BR112017007170A2 (Direct) |
| CA (1) | CA2963798A1 (Direct) |
| CL (1) | CL2017000885A1 (Direct) |
| CO (1) | CO2017004516A2 (Direct) |
| ES (1) | ES2914177T3 (Direct) |
| GB (1) | GB2536324A (Direct) |
| IL (1) | IL251537A0 (Direct) |
| MX (1) | MX2017004715A (Direct) |
| RU (1) | RU2709742C2 (Direct) |
| SG (1) | SG11201702826XA (Direct) |
| TW (1) | TW201619200A (Direct) |
| WO (1) | WO2016057667A1 (Direct) |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2976361T3 (en) | 2013-03-18 | 2018-10-01 | Biocerox Prod Bv | HUMANIZED ANTI-CD134- (0X40) ANTIBODIES AND APPLICATIONS THEREOF |
| JP2017501167A (ja) * | 2013-12-17 | 2017-01-12 | ジェネンテック， インコーポレイテッド | Ｏｘ４０結合アゴニスト及びｐｄ−１軸結合アンタゴニストを含む併用療法 |
| CA2943834A1 (en) | 2014-03-31 | 2015-10-08 | Genentech, Inc. | Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists |
| SMT201900702T1 (it) * | 2015-01-08 | 2020-01-14 | Genmab As | Agenti agonistici leganti il recettore del tnf |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| EA201792451A1 (ru) | 2015-05-07 | 2018-05-31 | Агенус Инк. | Антитела к ox40 и способы их применения |
| US20160347848A1 (en) * | 2015-05-28 | 2016-12-01 | Medimmune Limited | Therapeutic combinations and methods for treating neoplasia |
| WO2016196228A1 (en) | 2015-05-29 | 2016-12-08 | Bristol-Myers Squibb Company | Antibodies against ox40 and uses thereof |
| MX2018003820A (es) | 2015-10-02 | 2018-12-10 | F Hoffmann La Roche Ag | Anticuerpos biespecificos especificos para un receptor de tnf coestimulador. |
| JP6771551B2 (ja) | 2015-10-15 | 2020-10-21 | ディンフー バイオターゲット カンパニー リミテッド | 抗ｏｘ４０抗体及びその応用 |
| IL299072A (en) | 2015-12-02 | 2023-02-01 | Memorial Sloan Kettering Cancer Center | Antibodies and methods for using them |
| IL321475A (en) | 2016-05-06 | 2025-08-01 | Medimmune Llc | Bispecific binding proteins and their uses |
| ES3010640T3 (en) | 2016-06-20 | 2025-04-04 | Invox Pharma Ltd | Lag-3 binding members |
| BR112018076281A2 (pt) | 2016-06-20 | 2019-03-26 | Kymab Limited | imunocitocina, uso de uma imunocitocina, método, composição farmacêutica, método para tratar uma doença proliferativa em um animal, ácido nucleico, vetor, hospedeiro e anticorpo ou fragmento do mesmo |
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| MX2019000796A (es) * | 2016-07-20 | 2019-06-03 | Igm Biosciences Inc | Moleculas multimericas de union a ox40 y usos de las mismas. |
| CN109963871A (zh) | 2016-08-05 | 2019-07-02 | 豪夫迈·罗氏有限公司 | 具有激动活性的多价及多表位抗体以及使用方法 |
| CA3041340A1 (en) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
| US10556962B2 (en) | 2016-12-15 | 2020-02-11 | Abbvie Biotherapeutics Inc. | Anti-OX40 antibodies and their uses |
| AU2017384528A1 (en) | 2016-12-19 | 2019-07-04 | Ichnos Sciences SA | Novel TNFR agonists and uses thereof |
| WO2018178055A1 (en) | 2017-03-29 | 2018-10-04 | F. Hoffmann-La Roche Ag | Bispecific antigen binding molecule for a costimulatory tnf receptor |
| AU2018253950A1 (en) | 2017-04-20 | 2019-09-19 | Adc Therapeutics Sa | Combination therapy with an anti-CD25 antibody-drug conjugate |
| MX2019012464A (es) | 2017-04-20 | 2019-12-11 | Adc Therapeutics Sa | Terapia combinada con un conjugado de anticuerpo y farmaco anti-axl. |
| KR20200074214A (ko) * | 2017-11-01 | 2020-06-24 | 브리스톨-마이어스 스큅 컴퍼니 | 암을 치료하는데 사용하기 위한 면역자극 효능작용 항체 |
| AU2017440393B2 (en) * | 2017-11-24 | 2025-02-20 | Eucure (Beijing) Biopharma Co., Ltd | Anti-OX40 antibodies and uses thereof |
| KR102452246B1 (ko) | 2017-12-29 | 2022-10-12 | 에이피 바이오사이언시스, 아이엔씨. | 암 치료법을 위한 면역 체크포인트 조절을 갖는 단일특이성 및 이중특이성 단백질 |
| CN108218990B (zh) | 2017-12-29 | 2021-03-02 | 南京优迈生物科技有限公司 | 分离的抗体或其抗原结合片段及其在肿瘤治疗中的应用 |
| CN111393529B (zh) * | 2018-01-29 | 2022-02-22 | 康源博创生物科技(北京)有限公司 | 与ox40l非竞争结合的抗ox40抗体 |
| CA3093407A1 (en) | 2018-03-23 | 2019-09-26 | Bristol-Myers Squibb Company | Antibodies against mica and/or micb and uses thereof |
| WO2019178852A1 (zh) * | 2018-03-23 | 2019-09-26 | 苏州丁孚靶点生物技术有限公司 | Ox40抗原多肽及其用途 |
| CN120943884A (zh) | 2018-03-27 | 2025-11-14 | 百时美施贵宝公司 | 使用紫外线信号实时监测滴度 |
| AU2019264712A1 (en) | 2018-05-11 | 2021-01-07 | Wuxi Biologics (Shanghai) Co., Ltd. | Fully human antibodies against OX40, method for preparing same, and use thereof |
| EP3797123A4 (en) | 2018-05-23 | 2022-03-02 | BeiGene, Ltd. | ANTI-OX40 ANTIBODIES AND METHODS OF USE |
| MX2020012418A (es) | 2018-05-23 | 2021-04-28 | Adc Therapeutics Sa | Adyuvante molecular. |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| SG11202100172XA (en) | 2018-07-12 | 2021-02-25 | F Star Beta Ltd | Antibody molecules that bind cd137 and ox40 |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| CN112423845B (zh) | 2018-07-12 | 2024-07-30 | F-星治疗有限公司 | 结合pd-l1和cd137的抗体分子 |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| WO2020014583A1 (en) | 2018-07-13 | 2020-01-16 | Bristol-Myers Squibb Company | Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a mehtod of treating a cancer or a solid tumor |
| CN111040034B (zh) * | 2018-10-12 | 2022-08-30 | 广东旋玉健康生物科技有限公司 | 一种抗人cd358的单克隆抗体及其用途 |
| TW202028222A (zh) | 2018-11-14 | 2020-08-01 | 美商Ionis製藥公司 | Foxp3表現之調節劑 |
| EP3889180A4 (en) * | 2018-11-26 | 2023-01-04 | Nanjing GenScript Biotech Co., Ltd. | ANTI-OX40 HUMANIZED MONOCLONAL ANTIBODY, METHOD FOR PREPARATION AND USE |
| WO2020119789A1 (en) * | 2018-12-14 | 2020-06-18 | Wuxi Biologics (Shanghai) Co., Ltd. | Fully human antibodies against ox40, method for preparing the same, and use thereof |
| US12195545B2 (en) | 2018-12-25 | 2025-01-14 | Hanx Biopharmaceutics, Inc | Anti-OX40 monoclonal antibody and application thereof |
| US10442866B1 (en) * | 2019-01-23 | 2019-10-15 | Beijing Mabworks Biotech Co. Ltd | Antibodies binding OX40 and uses thereof |
| US20220135619A1 (en) | 2019-02-24 | 2022-05-05 | Bristol-Myers Squibb Company | Methods of isolating a protein |
| WO2020176771A1 (en) | 2019-02-27 | 2020-09-03 | Ionis Pharmaceuticals, Inc. | Modulators of malat1 expression |
| EP3946449A4 (en) * | 2019-03-25 | 2022-11-09 | Ohio State Innovation Foundation | COMBINED IMMUNOREGULATION AND ASSOCIATED USES |
| KR20220012292A (ko) | 2019-05-23 | 2022-02-03 | 브리스톨-마이어스 스큅 컴퍼니 | 세포 배양 배지를 모니터링하는 방법 |
| CN114174538A (zh) | 2019-05-30 | 2022-03-11 | 百时美施贵宝公司 | 适合于免疫肿瘤学疗法的多肿瘤基因特征 |
| CN114127315A (zh) | 2019-05-30 | 2022-03-01 | 百时美施贵宝公司 | 鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法 |
| US20220233691A1 (en) | 2019-05-30 | 2022-07-28 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
| MX2022006147A (es) * | 2019-11-21 | 2022-06-17 | Beigene Ltd | Metodos de tratamiento del cancer utilizando anticuerpos anti-ox40 en combinacion con anticuerpos anti-pd1 o anti-pdl1. |
| JP2023503230A (ja) * | 2019-11-21 | 2023-01-27 | ベイジーン リミテッド | Ｐｉ３キナーゼデルタ阻害剤との組合せで抗ｏｘ４０抗体を用いる癌治療の方法 |
| US20230002500A1 (en) * | 2019-11-21 | 2023-01-05 | Beigene, Ltd. | Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tigit antibodies |
| JP2023503031A (ja) * | 2019-11-21 | 2023-01-26 | ベイジーン（ベイジン）カンパニー リミテッド | 化学療法剤との組合せでの抗ｏｘ４０抗体による癌治療の方法 |
| KR20220103105A (ko) * | 2019-11-21 | 2022-07-21 | 베이진 엘티디 | 항-tim3 항체와 병용하여 항-ox40 항체를 사용한 암 치료 방법 |
| GB201917254D0 (en) | 2019-11-27 | 2020-01-08 | Adc Therapeutics Sa | Combination therapy |
| WO2021111636A1 (ja) * | 2019-12-06 | 2021-06-10 | 大塚製薬株式会社 | 抗ｇｄｆ１５抗体 |
| JOP20220151A1 (ar) | 2019-12-17 | 2023-01-30 | Amgen Inc | ناهض مستقبل إنترلوكين -2 / tnf المزدوج للاستخدام في العلاج |
| WO2021190431A1 (zh) | 2020-03-23 | 2021-09-30 | 百奥泰生物制药股份有限公司 | 一种免疫细胞激活剂的开发及应用 |
| KR20230015328A (ko) * | 2020-04-17 | 2023-01-31 | 허치슨 메디파르마 리미티드 | 항-ox40 항체 및 이의 용도 |
| WO2021228836A1 (en) | 2020-05-13 | 2021-11-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Recombinant proteins with ox40 activating properties |
| MX2023002326A (es) | 2020-08-31 | 2023-03-21 | Bristol Myers Squibb Co | Firma de localizacion celular e inmunoterapia. |
| CN116406369A (zh) | 2020-10-05 | 2023-07-07 | 百时美施贵宝公司 | 用于浓缩蛋白质的方法 |
| CN114457022A (zh) * | 2020-10-30 | 2022-05-10 | 未来智人再生医学研究院(广州)有限公司 | 一种表达ox40激活型抗体的多能干细胞及其衍生物与应用 |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| WO2022133169A1 (en) | 2020-12-18 | 2022-06-23 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| MX2023007650A (es) | 2020-12-28 | 2023-09-11 | Bristol Myers Squibb Co | Metodos de tratamiento de tumores. |
| HRP20250628T1 (hr) | 2020-12-28 | 2025-07-18 | Bristol-Myers Squibb Company | Mješavine antitijela i postupci njihove upotrebe |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
| EP4314068A1 (en) | 2021-04-02 | 2024-02-07 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| WO2023275616A1 (en) * | 2021-06-29 | 2023-01-05 | Hifibio (Hk) Limited | Anti-ox40 monoclonal antibody and methods of use thereof |
| EP4448578A4 (en) | 2021-12-17 | 2026-02-18 | Shanghai Henlius Biotech Inc | ANTI-OX40 ANTIBODIES, MULTI-SPECIFIC ANTIBODIES AND METHODS OF USE |
| WO2023109901A1 (en) | 2021-12-17 | 2023-06-22 | Shanghai Henlius Biotech, Inc. | Anti-ox40 antibodies and methods of use |
| WO2023152116A1 (en) | 2022-02-08 | 2023-08-17 | Hookipa Biotech Gmbh | Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines |
| JP2025509274A (ja) | 2022-03-09 | 2025-04-11 | ブリストル－マイヤーズ スクイブ カンパニー | 治療用タンパク質の一過性発現 |
| WO2023178329A1 (en) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
| CN114591988B (zh) * | 2022-03-30 | 2023-01-13 | 北京贝来生物科技有限公司 | 一种激活肿瘤免疫的基因修饰干细胞制备方法 |
| EP4531916A1 (en) | 2022-06-02 | 2025-04-09 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| CN114966061B (zh) * | 2022-07-28 | 2022-10-21 | 中国食品药品检定研究院 | 一种抗ox40抗体的生物活性检测方法 |
| EP4583999A1 (en) | 2022-09-09 | 2025-07-16 | Bristol-Myers Squibb Company | Methods of separating chelator |
| WO2024196952A1 (en) | 2023-03-20 | 2024-09-26 | Bristol-Myers Squibb Company | Tumor subtype assessment for cancer therapy |
| WO2025038763A1 (en) | 2023-08-15 | 2025-02-20 | Bristol-Myers Squibb Company | Ceramic hydroxyapatite chromatography flow through method |
| US20250215087A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg depleting agent |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681718A (en) | 1986-03-14 | 1997-10-28 | Celltech Limited | Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof |
| US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| US6242566B1 (en) | 1994-02-10 | 2001-06-05 | Board Of Trustees Of The Leland Stanford Junior University | Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells |
| US6312700B1 (en) | 1998-02-24 | 2001-11-06 | Andrew D. Weinberg | Method for enhancing an antigen specific immune response with OX-40L |
| EP1218408A4 (en) * | 1999-09-24 | 2003-02-26 | Human Genome Sciences Inc | 32 HUMAN, SECRETED PROTEINS |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
| US20080187954A1 (en) | 2004-03-10 | 2008-08-07 | Lonza Ltd. | Method For Producing Antibodies |
| CA2581208A1 (en) | 2004-08-30 | 2006-03-09 | Lonza Biologics Plc. | Affinity- plus ion exchange- chromatography for purifying antibodies |
| DK1877090T3 (da) | 2005-05-06 | 2014-04-14 | Providence Health System | Trimert ox40-immunoglobulin-fusionsprotein og fremgangsmåder til anvendelse heraf |
| TWI461436B (zh) * | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法 |
| MY150756A (en) * | 2006-08-21 | 2014-02-28 | Hoffmann La Roche | Tumor theraphy with an anti-vegf antibody |
| US7691980B2 (en) | 2007-01-09 | 2010-04-06 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
| AU2008219666A1 (en) * | 2007-02-27 | 2008-09-04 | Genentech, Inc. | Antagonist OX40 antibodies and their use in the treatment of inflammatory and autoimmune diseases |
| DK2242771T3 (da) * | 2007-12-14 | 2013-08-26 | Pfizer | Bindingsmolekyler til den humane ox40-receptor |
| WO2009092014A1 (en) | 2008-01-18 | 2009-07-23 | Gagnon Peter S | Enhanced purification of antibodies and antibody fragments by apatite chromatography |
| MX2010008578A (es) | 2008-02-08 | 2010-11-10 | Medimmune Llc | Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc. |
| SG2014014708A (en) * | 2009-02-17 | 2014-05-29 | Ucb Pharma Sa | Antibody molecules having specificity for human ox40 |
| WO2013028231A1 (en) | 2011-08-23 | 2013-02-28 | Board Of Regents, The University Of Texas System | Anti-ox40 antibodies and methods of using the same |
| DK3604339T3 (da) * | 2011-01-14 | 2021-04-12 | Univ California | Terapeutiske antistoffer mod ror-1-protein og fremgangsmåder til anvendelse af samme |
| CA3158257A1 (en) * | 2011-07-11 | 2013-01-17 | Ichnos Sciences SA | Antibodies that bind to ox40 and their uses |
| GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
| US9828432B2 (en) | 2012-02-06 | 2017-11-28 | Providence Health & Services—Oregon | Cancer treatment and monitoring methods using OX40 agonists |
| HK1205691A1 (en) * | 2012-03-02 | 2015-12-24 | Providence Health & Services - Oregon | Dual ox40 agonist/il-2 cancer therapy methods |
| US9409977B2 (en) * | 2013-03-12 | 2016-08-09 | Decimmune Therapeutics, Inc. | Humanized, anti-N2 antibodies |
| DK2976361T3 (en) * | 2013-03-18 | 2018-10-01 | Biocerox Prod Bv | HUMANIZED ANTI-CD134- (0X40) ANTIBODIES AND APPLICATIONS THEREOF |
-
2015
- 2015-10-01 TW TW104132442A patent/TW201619200A/zh unknown
- 2015-10-07 MX MX2017004715A patent/MX2017004715A/es unknown
- 2015-10-07 CN CN201580056175.7A patent/CN107074953A/zh active Pending
- 2015-10-07 RU RU2017115662A patent/RU2709742C2/ru active
- 2015-10-07 EP EP15848683.7A patent/EP3204422B1/en active Active
- 2015-10-07 AU AU2015328090A patent/AU2015328090A1/en not_active Abandoned
- 2015-10-07 CA CA2963798A patent/CA2963798A1/en not_active Abandoned
- 2015-10-07 ES ES15848683T patent/ES2914177T3/es active Active
- 2015-10-07 WO PCT/US2015/054490 patent/WO2016057667A1/en not_active Ceased
- 2015-10-07 BR BR112017007170A patent/BR112017007170A2/pt not_active Application Discontinuation
- 2015-10-07 JP JP2017518907A patent/JP6794348B2/ja active Active
- 2015-10-07 US US14/877,547 patent/US9738723B2/en active Active
- 2015-10-07 KR KR1020177012413A patent/KR20170064550A/ko not_active Withdrawn
- 2015-10-07 SG SG11201702826XA patent/SG11201702826XA/en unknown
- 2015-10-08 GB GB1517855.1A patent/GB2536324A/en not_active Withdrawn
- 2015-10-09 AR ARP150103284A patent/AR102239A1/es unknown
-
2017
- 2017-04-03 IL IL251537A patent/IL251537A0/en unknown
- 2017-04-10 CL CL2017000885A patent/CL2017000885A1/es unknown
- 2017-05-04 CO CONC2017/0004516A patent/CO2017004516A2/es unknown
- 2017-06-28 US US15/635,847 patent/US10150815B2/en active Active
-
2018
- 2018-12-10 US US16/215,263 patent/US20190169303A1/en not_active Abandoned
-
2020
- 2020-11-11 JP JP2020187650A patent/JP2021036887A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017532037A5 (Direct) | ||
| RU2017115662A (ru) | Гуманизированные антитела к ox40 и способы их применения | |
| KR102503084B1 (ko) | 항-ctla4 및 항-pd-1 이작용성 항체, 이의 약제학적 조성물 및 이의 용도 | |
| KR102469286B1 (ko) | 항-pd1 단일클론 항체, 이의 약제학적 조성물 및 이의 용도 | |
| JP6976322B2 (ja) | 新規抗ｃｔｌａ４抗体 | |
| KR102068600B1 (ko) | Pdl-1 항체, 그 약학적 조성물 및 그 용도 | |
| JP2022160404A (ja) | ヒトｉｌ－４受容体に対する高親和性ヒト抗体 | |
| AU2014238546C1 (en) | Humanized anti-CD134 (OX40) antibodies and uses thereof | |
| JP2020520665A5 (Direct) | ||
| WO2016191643A4 (en) | Tigit-binding agents and uses thereof | |
| CN110669135B (zh) | 一种双特异性抗体及其用途 | |
| KR20190117493A (ko) | 항 pd-1 항체 및 그의 용도 | |
| WO2018106529A1 (en) | Anti-tim-3 antibodies for combination with anti-pd-l1 antibodies | |
| EP3892634A1 (en) | Anti-cd40 antibody, antigen binding fragment and pharmaceutical use thereof | |
| EP3668898A1 (en) | Humanized antibodies for cd3 | |
| IL254223B1 (en) | CD20 binding compounds and their uses | |
| CN110003338B (zh) | 抗ox40抗体及其应用 | |
| HRP20210393T1 (hr) | Anti-tfr antitijela i njihova uporaba u liječenju proliferativnih i upalnih poremećaja | |
| RU2010107175A (ru) | Антитела человека к cd20 человека и способ их использования | |
| HRP20221226T1 (hr) | Protutijela protiv pd-1 i postupci njihove upotrebe | |
| CN104903352A (zh) | 多价结合蛋白组合物 | |
| CN111183159A (zh) | 靶向cd137的抗体及其使用方法 | |
| IL272770B2 (en) | Agonistic cd40 antibodies | |
| TW202313682A (zh) | 抗icos抗體之用途 | |
| CN116194471A (zh) | 抗pd-1抗体和融合蛋白 |